Sarepta Therapeutics Receives Complete Response Letter from the FDA for Golodirsen New Drug Application
PPMD is very disappointed to learn that Sarepta Therapeutics received a Complete Response Letter from the FDA regarding the New Drug Application (NDA) seeking accelerated approval of golodirsen injection for the treatment of Duchenne in…Learn More